Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Crossref DOI link: https://doi.org/10.1038/nrd.2017.227
Published Online: 2017-12-01
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Carter, Paul J.
Lazar, Greg A.
Text and Data Mining valid from 2017-12-01
Article History
First Online: 1 December 2017
Competing interests
: The authors are employees of Genentech, a member of the Roche Group that develops and commercializes therapeutics including antibody-based drugs.